Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.

Leelarathna L, Ashley D, Fidler C, Parekh W.

Ther Adv Endocrinol Metab. 2018 Jul;9(7):187-197. doi: 10.1177/2042018818766816. Epub 2018 Apr 4.

2.

Beaming in Charcot Arthropathy-Intramedullary Fixation for Complicated Reconstructions: A Cadaveric Study.

Fidler CM, Watson BC, Reb CW, Hyer CF.

J Foot Ankle Surg. 2017 Jul - Aug;56(4):802-804. doi: 10.1053/j.jfas.2017.04.009.

PMID:
28633781
3.

Casual or Causal? Two Unique Cases of Hodgkin's Lymphoma: A Case Report and Literature Review.

Malik F, Ali N, Jafri SIM, Fidler C.

Am J Case Rep. 2017 May 19;18:553-557. Review.

4.

Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.

Malik F, Ali N, Jafri SIM, Ghani A, Hamid M, Boigon M, Fidler C.

J Med Case Rep. 2017 Apr 24;11(1):119. doi: 10.1186/s13256-017-1278-3.

5.

Eculizumab refractory thrombotic thrombocytopenic purpura secondary to post-endoscopic retrograde cholangiopancreatography pancreatitis in a patient.

Malik F, Ali N, Ahsan I, Ghani AR, Fidler C.

J Community Hosp Intern Med Perspect. 2016 Dec 15;6(6):32310. doi: 10.3402/jchimp.v6.32310. eCollection 2016.

6.

Clinical Adaptation of the "Tibiofibular Line" for Intraoperative Evaluation of Open Syndesmosis Reduction Accuracy: A Cadaveric Study.

Reb CW, Hyer CF, Collins CL, Fidler CM, Watson BC, Berlet GC.

Foot Ankle Int. 2016 Nov;37(11):1243-1248. Epub 2016 Aug 16.

PMID:
27530983
7.

Rethink Your Drink.

Hartigan P, Patton-Ku D, Fidler C, Boutelle KN.

Health Promot Pract. 2017 Mar;18(2):238-244. doi: 10.1177/1524839915625215. Epub 2016 Jul 9.

8.

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.

Elliott L, Fidler C, Ditchfield A, Stissing T.

Diabetes Ther. 2016 Mar;7(1):45-60. doi: 10.1007/s13300-016-0157-z. Epub 2016 Feb 17.

9.

Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus.

Werzowa J, Pacini G, Hecking M, Fidler C, Haidinger M, Brath H, Thomas A, Säemann MD, Tura A.

J Diabetes Complications. 2015 Nov-Dec;29(8):1211-6. doi: 10.1016/j.jdiacomp.2015.07.014. Epub 2015 Jul 17.

PMID:
26264400
10.

Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women.

Sanfilippo KM, McTigue KM, Fidler CJ, Neaton JD, Chang Y, Fried LF, Liu S, Kuller LH.

Hypertension. 2014 May;63(5):934-41. doi: 10.1161/HYPERTENSIONAHA.113.02953. Epub 2014 Mar 17.

11.

Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant.

Fidler C, Klumpp T, Mangan K, Martin M, Sharma M, Emmons R, Lu M, Kropf P.

Am J Hematol. 2012 Feb;87(2):219-21. doi: 10.1002/ajh.22227. Epub 2011 Dec 21.

12.

Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Dakin H, Sherman M, Fung S, Fidler C, Bentley A.

Pharmacoeconomics. 2011 Dec;29(12):1075-91. doi: 10.2165/11589260-000000000-00000.

PMID:
22077579
13.

Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs.

Fidler C, Elmelund Christensen T, Gillard S.

J Med Econ. 2011;14(5):646-55. doi: 10.3111/13696998.2011.610852. Epub 2011 Aug 19. Review.

PMID:
21854191
15.

Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.

Dakin H, Fidler C, Harper C.

Value Health. 2010 Dec;13(8):934-45. doi: 10.1111/j.1524-4733.2010.00777.x. Epub 2010 Sep 3.

16.

Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.

Menown I, Montalescot G, Pal N, Fidler C, Orme M, Gillard S.

Adv Ther. 2010 Mar;27(3):181-91. doi: 10.1007/s12325-010-0013-x. Epub 2010 Apr 23.

PMID:
20422473
17.

The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden.

Christensen T, Fidler C, Bentley A, Djurhuus C.

J Med Econ. 2010 Mar;13(1):168-78. doi: 10.3111/13696991003652248.

PMID:
20136580
18.

Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.

Wang L, Fidler C, Nadig N, Giagounidis A, Della Porta MG, Malcovati L, Killick S, Gattermann N, Aul C, Boultwood J, Wainscoat JS.

Haematologica. 2008 Jul;93(7):994-1000. doi: 10.3324/haematol.12603. Epub 2008 May 27.

19.

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.

Pellagatti A, Hellström-Lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Fidler C, Cazzola M, Wainscoat JS, Boultwood J.

Br J Haematol. 2008 Jul;142(1):57-64. doi: 10.1111/j.1365-2141.2008.07178.x. Epub 2008 May 8. Erratum in: Br J Haematol. 2009 Feb;144(3):455.

20.

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.

Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, Cattan H, Littlewood TJ, Malcovati L, Della Porta MG, Jädersten M, Killick S, Giagounidis A, Bowen D, Hellström-Lindberg E, Cazzola M, Wainscoat JS.

PLoS One. 2008 Apr 9;3(4):e1970. doi: 10.1371/journal.pone.0001970.

21.

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.

Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Fidler C, Cazzola M, Hellström-Lindberg E, Wainscoat JS.

Br J Haematol. 2007 Nov;139(4):578-89. Epub 2007 Oct 3.

PMID:
17916100
22.

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, Campbell LJ, Wang L, Langford CF, Fidler C, Oscier D, Aul C, Wainscoat JS, Boultwood J.

Blood. 2006 Jul 1;108(1):337-45. Epub 2006 Mar 9. Erratum in: Blood. 2006 Aug 15;108(4):1128.

PMID:
16527891
23.

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.

Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J.

Leukemia. 2006 Apr;20(4):671-9.

PMID:
16498395
24.

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN.

Vaccine. 2006 Jan 12;24(2):116-23. Epub 2005 Aug 18.

PMID:
16140433
25.

Gene expression profiling in the myelodysplastic syndromes.

Pellagatti A, Fidler C, Wainscoat JS, Boultwood J.

Hematology. 2005 Aug;10(4):281-7. Review.

PMID:
16085540
26.

The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.

Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, Lapointe C, Hamlet S, Chatfield SN.

J Infect Dis. 2005 Aug 1;192(3):360-6. Epub 2005 Jun 30.

PMID:
15995948
27.

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.

Boultwood J, Pellagatti A, Watkins F, Campbell LJ, Esoof N, Cross NC, Eagleton H, Littlewood TJ, Fidler C, Wainscoat JS.

Br J Haematol. 2004 Aug;126(4):508-11.

PMID:
15287943
28.

Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.

Watkins F, Fidler C, Boultwood J, Wainscoat JS.

Am J Hematol. 2004 Aug;76(4):417. No abstract available.

29.

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Fidler C, Watkins F, Bowen DT, Littlewood TJ, Wainscoat JS, Boultwood J.

Haematologica. 2004 Jul;89(7):865-6.

30.

Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology.

Pellagatti A, Esoof N, Watkins F, Langford CF, Vetrie D, Campbell LJ, Fidler C, Cavenagh JD, Eagleton H, Gordon P, Woodcock B, Pushkaran B, Kwan M, Wainscoat JS, Boultwood J.

Br J Haematol. 2004 Jun;125(5):576-83.

PMID:
15147372
31.

Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR.

Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, Harris AL, Wainscoat JS.

Br J Cancer. 2004 Mar 22;90(6):1211-5.

32.

p73 gene mutations in gastric adenocarcinomas.

Pilozzi E, Talerico C, Platt A, Fidler C, Ruco L.

Mol Pathol. 2003 Feb;56(1):60-2.

33.

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.

Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N, Hughes G, Salamanchuk Z, Calasanz MJ, Lahortiga I, Pocock CF, Dang R, Fidler C, Wainscoat JS, Boultwood J, Cross NC.

Br J Haematol. 2003 Jan;120(2):251-6.

PMID:
12542482
34.

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, Tosi S, Kasprzyk A, Cheng JF, Jaju RJ, Wainscoat JS.

Blood. 2002 Jun 15;99(12):4638-41.

PMID:
12036901
35.

Mutation analysis of cancer using automated sequencing.

Strickson A, Fidler C.

Methods Mol Med. 2002;68:171-7. No abstract available.

PMID:
11901501
36.

Collaboration to implement smoking cessation guidelines during the childbirth continuum.

Saks NP, Hartigan P, Howard N, Schneider JM, Nathan G, Fidler C, Beck CH Jr.

Jt Comm J Qual Improv. 2001 Dec;27(12):664-72.

PMID:
11765383
37.

The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, Jones M, Mason DY, Prime JE, Trougouboff P, Wood K, Cordell JL.

Cancer Res. 2001 Dec 15;61(24):8820-9.

38.

Detection of Plasmodium falciparum DNA in plasma.

Gal S, Fidler C, Turner S, Lo YM, Roberts DJ, Wainscoat JS.

Ann N Y Acad Sci. 2001 Sep;945:234-8.

PMID:
11708485
39.

Detection of mammaglobin mRNA in the plasma of breast cancer patients.

Gal S, Fidler C, Lo YM, Chin K, Moore J, Harris AL, Wainscoat JS.

Ann N Y Acad Sci. 2001 Sep;945:192-4.

PMID:
11708478
40.
41.

A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia.

Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K, Cross NC, Cheng JF, Aplan PD, Kearney L, Boultwood J, Wainscoat JS.

Blood. 2001 Aug 15;98(4):1264-7.

PMID:
11493482
42.
43.

Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q- syndrome within 5q32, and immediately adjacent to the SPARC gene.

Boultwood J, Strickson AJ, Jabs EW, Cheng JF, Fidler C, Wainscoat JS.

Hum Genet. 2000 Jan;106(1):127-9.

PMID:
10982193
44.

Mutation analysis of the SPARC gene in the 5q-syndrome.

Fidler C, Strickson A, Boultwood J, Waincoat JS.

Am J Hematol. 2000 Aug;64(4):324. No abstract available.

45.

Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.

Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ, Wainscoat JS.

Blood. 2000 Jul 1;96(1):358-61.

PMID:
10891474
46.

Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs.

Boultwood J, Fidler C, Strickson AJ, Watkins F, Kostrzewa M, Jaju RJ, Müller U, Wainscoat JS.

Genomics. 2000 May 15;66(1):26-34.

PMID:
10843801
47.

Determination of fetal RhD status by maternal plasma DNA analysis.

Zhang J, Fidler C, Murphy MF, Chamberlain PF, Sargent IL, Redman CW, Hjelm NM, Wainscoat JS, Lo YM.

Ann N Y Acad Sci. 2000 Apr;906:153-5. No abstract available.

PMID:
10818612
48.

Gene rearrangements in T-cell lymphoblastic lymphoma.

Pilozzi E, Müller-Hermelink HK, Falini B, de Wolf-Peeters C, Fidler C, Gatter K, Wainscoat J.

J Pathol. 1999 Jul;188(3):267-70.

PMID:
10419594
49.

Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.

Boultwood J, Fidler C, Shepherd P, Watkins F, Snowball J, Haynes S, Kusec R, Gaiger A, Littlewood TJ, Peniket AJ, Wainscoat JS.

Am J Hematol. 1999 May;61(1):5-9.

50.

The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.

Fidler C, Wainscoat JS, Boultwood J.

Genomics. 1999 Feb 15;56(1):134-6. No abstract available.

PMID:
10036195

Supplemental Content

Loading ...
Support Center